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The current knowledge of pathophysiology and new medications, as well as the
better use of old ones, has significantly improved the therapy and prognosis of patients
with bronchial asthma. However, it should be
understood that drug therapy is beneficial only
when aggravating or precipitating agents have
been eliminated from the patient's environment;
these include allergens, such as dust, mold,
pollens and other irritants, infection, exercise,
psychological disturbances, certain drugs (aspirin}, and stimulation of irritant receptors in the
respiratory tract.
There are five major classes of drugs used
in treating bronchial asthma: ( 1) adrenergic
agents, (2) xanthines, (3) corticosteroids, (4)
cromolyn sodium, and (5) parasympatholytic
agents. Some adrenergic agents, such as terbutaline and metaproterenol, offer advantages
over others, such as epinephrine , isoproterenol
and ephedrine . Among the xanthines the measurement of theophylline blood levels has resulted in the more effective use of aminophylline
and other theophylline compounds. The development of a topical steroid, beclomethasone,
has been useful in treating steroid-dependent
chronic asthmatics. The drugs described below
are prescribed to eliminate wheezing and dyspnea; however, other types of therapy such as
antibiotics for infections, hyposensitization for
allergic factors, and counseling for emotional
disturbances should also be considered.
Correspondence and reprint requests to Dr. Orhan
Muren, Box 4 72, Medical College of Virginia, Richmond,
VA 23298.

Adrenergic Drugs

Adrenergic agents reduce bronchial obstruction by activating the enzyme adenylcyclase, which increases cyclic adenosine monophosphate (cAMP) in bronchial smooth muscle
and mast cells. Adrenergic drugs have alphaand beta-stimulating effects. The stimulation of
alpha receptors causes vasoconstriction. Beta
receptors are divided into beta, and beta2 receptors. The stimulation of beta, receptors
causes cardiac stimulation; stimulation of beta 2
receptors is responsible for bronchodilatation,
as well as other effects. Terbutaline and metaproterenol are primarily " beta2 -selective," but
they also stimulate the heart minimally.
Terbutaline (Brethine; Bricanyl}, which
comes in tablets and ampules is, as noted
above, a selective beta2 agent. The most common side effect is tremor, which is caused by
stimulation of beta2 receptors in the skeletal
muscle. It is recommended that this drug be
started at 2.5 mg every eight hours. Tremor
may disappear after continuation of the medication; thereafter the dose can be increased to 5
mg every eight hours. However, it should be
kept in mind that an injection dose of O.2 5 mg
of terbutaline may also cause a significant degree of cardiac stimulation.
Metaproterenol (Alupent) is available as
a syrup, in tablets and as an aerosol; tremor is a
common side effect. The usual oral dose is 1 0
to 20 mg q.8.h.
lsoetharine (Bronkosol; Bronkometer) is
available as an aerosol.
Epinephrine and isoproterenol have
been used for a long time in the management of
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patients with bronchial asthma. Epinephrine has
both alpha- and beta 1- and beta 2 -stimulating effects. lsoproterenol stimulates both beta 1 and
beta 2 receptors. Epinephrine may also improve
symptoms by constricting vessels in the bronchial mucosa, thus decreasing edema. However, epinephrine increases blood pressure,
and large doses of this agent or isoproterenol
can cause angina pectoris and cardiac arrythmias . It has been observed that cardiac
stimulation may increase blood flow in some regions of the lung where there may be poor ventilation . This may cause lowering of arterial 0 2
tension.
Ephedrine. This drug was the first adrenergic agent used and it stimulates both alpha
and beta receptors. However, its bronchodilatation activity is less than that of the new beta 2
agents. Ephedrine may increase blood pressure
and may cause CNS stimulation (insomnia, nervousness). It may be responsible for urinary retention in patients with some degree of prostatic
obstruction. Ephedrine and isoproterenol have
more beta- 1 (cardiac stimulation) than the newer
medications . Insomnia, palpitations, and anxiety limit their use in bronchial asthma .

Xanthines
Theophylline is 1 ,3 dimethylxanthine.
Methylxanthines increase intracellular cAMP by
inhibiting phosphodiesterases , enzymes responsible for the breakdown of cAMP. Theophylline has been used for many years in combination with ephedrine and a sedative. The
combination medications provide one fourth to
one half the proper dose of theophylline and
less bronchodilatation.
Aminophylline is theophylline ethylenediamine and is used more often than theophylline itself. Since the difference between
therapeutic and toxic doses of theophylline
compounds may be narrow, it is desirable to
start with a small dose and increase it as required . Plasma theophylline levels should be
obtained if patients do not respond to the usual
doses; the optimum serum level is between 1 0
and 20 µg / ml. 1 Patients with chronic liver disease should be treated carefully, since theophylline is detoxified in the liver. Serum theophylline levels greater than 20 µg/ml are
usually associated with toxic side effects, such
as nausea, vomiting, anorexia, headache, tachycardia and CNS irritation . Levels greater than
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30 to 40 µg/ml may lead to serious cardiac arrythmias and seizures.
An oral loading dose of approximately 5
to 6 mg/kg of aminophylline, anhydrous theophylline, or elixophylline will supply therapeutic
theophylline levels within 30 to 45 minutes and
will usually be effective against a mild-to-moderate degree of bronchospasm. In cases of severe bronchospasm 6 mg/kg aminophylline
should be given intravenously in a drip over 20
minutes.
The usual recommended intravenous (IV)
maintenance of theophylline is 0 .9 mg/kg/hr
aminophylline . Serum theophylline levels should
be checked at 1 8 to 24 hours and proper adjustments made as needed. In patients with
congestive heart failure or liver disease, the
dose should be reduced by half or more if indicated. In elderly people intravenous maintenance of theophylline is 0. 7 mg/kg/hr.
For long-term maintenance of theophylline
an average-size adult patient with bronchial
asthma requires approximately 800 to 1 200
mg/day aminophylline. The serum levels
should be checked after three days on this therapy, and proper adjustments should be made to
maintain levels between 1 0 to 20 µg/ml. The
slow-release preparations of theophylline can
be given every 1 2 hours and can be effective
against early-morning bronchospasm .

Corticosteroids
Steroids are very useful in the treatment of
asthma but should be used only when conventional bronchodilating agents fail to relieve bronchospasm. Some of the undesirable side effects
of steroids include acne, peptic ulcer, osteoporosis , growth retardation , hypertension, adrenal suppression and opportunistic infections.
The exact mechanism of steroid action in
asthma is not definitely known . Large doses appear to potentiate beta agonists and cause
bronchodilatation. As soon as symptoms are relieved with up to 60 to 80 mg/day of prednisone or prednisolone , the dose is tapered to the
smallest effective dose , 5 to 1 0 mg/day or 1 0
to 20 mg every other day.
Beclomethasone dipropionate (Vanceril) is a topically active , inhaled steroid (50
µg/puff , 8 to 20 puffs per day). When used
properly it has no, or only minimal, systemic effects and is especially useful in steroid-dependent chronic asthmatics. It is most effective
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when the patient is relatively free of asthma .
The usual dose is two puffs four times a day.
The patient continues to take all previous medications . If the patient improves after two weeks,
steroids should be decreased slowly. If no improvement takes place, the dosage may be increased to four puffs four times a day and then
decreased after two weeks of symptomatic improvement . Sixteen hundred micrograms or
greater per day causes adrenal suppression . By
proper administration of beclomethasone in
many steroid-dependent asthmatics, the steroid
dose can be significantly reduced and even discontinued . The main possible adverse effects of
this agent are nasopharyngeal candidiasis and,
in patients who have been on long-term systemic steroids, adrenocortical insufficiency as
adrenal suppressive doses of corticosteroids
are decreased . Oral candidiasis can be minimized by rinsing the oral cavity after each use
with plain water; if candidiasis occurs, nystatin
(Mycostatin) rinse three times a day will eradicate the infection .

Cromolyn Sodium
Cromolyn blocks the release of chemical
mediators from the sensitized mast cells; it has
no antihistamine, bronchodilator or anti-inflammatory characteristics and should not be used
during an acute asthmatic attack. It has only
prophylactic value . The main indication in the
asthmatic appears to be as a steroid-sparing
agent. It is most useful in young patients with
extrinsic or exercise-induced asthma. The usual
dose is 20 mg four times a day by a special inhaler. 2 If after four weeks of therapy, no improvement occurs, the drug should be disconti nued. The adverse side effects include cough,
th roat irritation, skin rashes, occasionally bronch ospasm, and eosinophilic pneumonia .
Parasympatholytic Agents
A parasympatholytic agent, such as ipratropium (SCH-1 000/ Atrovent, 40 µg/puff) may
give bronchodilatation in asthma and chronic
bronchitis. It is not available in the United States
at the present time .
Combination of Drugs
A beta agonist such as terbutaline can be
given with theophylline, and lower doses of the
two together may be as effective or less toxic
th an higher doses of either drug alone. Oral

bronchodilating agents are usually continued
when patients receive corticosteroids or cromolyn sodium .

Indications of Severity of Bronchial Asthma
Significant reduction in FEV 1 (less than
1 . 0 liter) associated with one or more abnormalities such as marked scalene muscle contractions, mental confusion , pulse rate greater
than 130/min, pulsus paradoxus greater than
1 0 mm Hg, marked overdistension of the
lungs on chest x-ray, central cyanosis, arterial
PC02 greater than 40 mm Hg, pneumothorax ,
or pneumomediastinum , indicate a severe attack of asthma .3 If FEV 1 is less than 25% predicted, there is a tendency to C0 2 retention .
Pulsus paradoxus of more than 1 0 torr is associated with FEV1 less than 25% predicted ; scalene muscle contractions and intercostal retractions suggest FEV 1 less than 1 . O liter.4
Patients with these abnormalities should
be hospitalized immediately, and receive proper
therapy (IV aminophylline, high doses of steroids, supportive and specific care) .
Status asthmaticus is defined as a severe
asthma attack unresponsive to inhaled or injected sympathomimetic amines. The cornerstone of management of status asthmaticus is
the administration of IV aminophylline and large
doses of corticosteroids . Supportive care and
specific therapy for any complication should
also be undertaken.
Indications for Intubation and Mechanical
Ventilation in Asthma.
1 . Arterial PC0 2 over 50 to 60 torr in the
absence of chronic hypercapnea.
2. An arterial P0 2 under 60 torr on 6 liters of 0 2 by nasal cannula .
3. Evidence of marked increase in the
work of breathing judged by physical
examination, even in the presence of
near-normal arterial gas studies.
4. Respiratory arrest.
It should be emphasized that during the
acute episode of an asthma attack, there is a
lowering of arterial P0 2 and PC0 2 . Perfectly
normal PC0 2 such as 40 torr indicates fatigue
of the patient and the necessity of aggressive
therapy .
Treatment Failures
Patient compliance and understanding are
important for the successful management of
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asthma. Hidden environmental hazards should
be eliminated. Not every wheezing represents
bronchial asthma; left-sided heart failure ,
chronic obstructive pulmonary disease, pulmonary emboli, hypersensitivity pneumonitis, mediastinal node compression, foreign body in a
large bronchus, or bronchial carcinoid can be
responsible for diffuse wheezing masquerading
as asthma . Finally, inadequate medication may
be the cause of failure to improve. Readings of
serum theophylline at the level obtained one
hour after a dose has been given, and one hour
before the next dose , are helpful indications of
whether an adequate amount has been given
There is a tendency to underuse corticosteroids
in severe acute respiratory failure . It is better to
overuse the steroids for a short period than to

have the patient suffer cardiac, respiratory or
neurologic damage if complications arise.
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